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0.02) surgery compared to the inverse of creatinine (before: 
r = 0.26, p = 0.13; after: r = 0.11, p = 0.51). mGFR fell by 17 ± 
35 ml/min (p = 0.007) following surgery. The CKD-EPI creat-cystC 
was unquestionably the best overall performing estimating 
equation before and after surgery, revealing very little bias 
and a capacity to estimate mGFR within 30% of its true value 
over 80% of the time. This was true whether or not mGFR was 
indexed for body surface area.  Conclusions: In severely 
obese bariatric surgery patients with normal kidney func-
tion, cystatin C is more strongly associated with mGFR than 
is serum creatinine. The CKD-EPI creat-cystC equation best pre-
dicted mGFR both before and after surgery. 
 © 2013 S. Karger AG, Basel 
 Introduction 
 Bariatric surgery is a common and effective treatment 
for severe obesity, a problem of global proportions that is 
linked to a variety of adverse clinical outcomes  [1] . Bar-
iatric surgery is of interest to nephrologists not only be-
cause it is associated with an increased risk for both acute 
and chronic kidney injury  [2] but also because it serves as 
a research model to investigate the relationship between 
obesity, weight reduction and kidney health. Investiga-
tions using the bariatric surgery model suggest that weight 
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 Abstract 
 Background/Aims: Identifying the best method to estimate 
the glomerular filtration rate (GFR) in bariatric surgery pa-
tients has important implications for the clinical care of 
obese patients and research into the impact of obesity and 
weight reduction on kidney health. We therefore performed 
such an analysis in patients before and after surgical weight 
loss.  Methods: Fasting measured GFR (mGFR) by plasma io-
hexol clearance before and after bariatric surgery was ob-
tained in 36 severely obese individuals. Estimated GFR was 
calculated using the Modification of Diet in Renal Disease 
equation, the Chronic Kidney Disease Epidemiology Collab-
oration (CKD-EPI) equation using serum creatinine only, the 
CKD-EPI equation using serum cystatin C only and a recently 
derived equation that uses both serum creatinine and cys-
tatin C (CKD-EPI creat-cystC ) and then compared to mGFR.  Re-
sults: Participants were primarily middle-aged white fe-
males with a mean baseline body mass index of 46 ± 9, se-
rum creatinine of 0.81 ± 0.24 mg/dl and mGFR of 117 ± 40 
ml/min. mGFR had a stronger linear relationship with inverse 
cystatin C before (r = 0.28, p = 0.09) and after (r = 0.38, p = 
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loss in obese persons may have renoprotective effects  [3, 
4] , although the body of evidence relies primarily on es-
timated glomerular filtration rate (eGFR) rather than di-
rectly measured GFR (mGFR). Similarly, clinical evalua-
tions of bariatric surgery patients also depend on eGFR.
 Unfortunately, the value of eGFR in bariatric surgery 
patients using standard estimating equations, the most 
common clinical method, may be limited. There are sev-
eral reasons for this. Firstly, the equations were derived 
from mostly nonobese populations  [5–7] . Because serum 
creatinine is derived from muscle mass, and the muscle 
mass of severely obese individuals is greater than that of 
leaner individuals of similar height, this could adversely 
affect the reliability of the equations  [8] . Additionally, 
weight loss after surgery involves reductions in muscle as 
well as fat mass  [9] . Further complicating this issue is the 
fact that elevations in glomerular filtration (often called 
hyperfiltration), which cause a drop in serum creatinine 
levels, are frequently observed in obese individuals and 
reversed when weight is lost  [10] . Cystatin C, an alterna-
tive endogenous marker of glomerular filtration, is argu-
ably not as influenced by muscle mass as is serum creati-
nine  [11] , so it may be a more reliable indicator of kidney 
function in obese individuals. However, it is notable that 
none of the best validated creatinine- or cystatin-based 
estimating equations has been carefully evaluated in very 
obese or bariatric surgery patients.
 We therefore assessed the reliability of the most prom-
inent GFR equations and endogenous GFR markers in a 
cohort of severely obese patients with putatively normal 
kidney function before and after bariatric surgery by 
comparing eGFR to mGFR. We hypothesized that cys-
tatin C-based eGFR would better predict mGFR than es-
timations based on serum cystatin C.
 Subjects and Methods 
 Participants 
 Study participants were part of several research projects per-
formed between 2004 and 2011  [12, 13, 44] and were recruited 
from bariatric surgery clinics in the Indianapolis (Ind., USA) area. 
All subjects except 1 [body mass index (BMI) of 33] were severely 
obese, defined as a BMI  ≥ 35. The relevant institutional review 
boards approved the protocol (NCT00244790), and all patients 
gave written informed consent after reviewing a written summary 
of the plan. The study adhered to the Declaration of Helsinki. A 
data safety and monitoring board oversaw the study. Inclusion cri-
teria included age 18 or greater, ability to give informed consent 
and a BMI of 30 or higher. Exclusion criteria included pregnancy, 
an iodine allergy, a diagnosis of diabetes mellitus, use of an angio-
tensin-converting enzyme inhibitor or angiotensin receptor block-
er, serum creatinine >1.3 mg/dl for women and >1.5 mg/dl for 
men, or dialysis dependency. Pregnancy was excluded by a urine 
pregnancy test on the day of study. Presurgery measurements were 
performed within the 6-month period prior to surgery, and post-
surgery measurements were performed at varying time points de-
pending upon the study protocol (several months to over 1 year), 
with the mean postoperative measurement time point being ap-
proximately 10 months.
 Measurements 
 mGFR was calculated from plasma iohexol (Omnipaque-300, 
GE Healthcare, Piscataway, N.J., USA) clearance. Plasma was iso-
lated and stored at –80  °  C until measured by capillary electropho-
resis using a Model 2050 CE instrument (Beckman Instruments, 
Palo Alto, Calif., USA) as previously reported  [12, 13] or HPLC 
(Agilent 1100, Santa Clara, Calif., USA) with UV detection. Indi-
vidual iohexol clearances (milliliters per minute) were estimated 
by standard noncompartmental methods using Phoenix WinNon-
lin (Pharsight, Cary, N.C., USA). Iohexol clearance was calculated 
as dose divided by the area under the plasma concentration-time 
curve from time zero to infinity. In cases where only 2 plasma con-
centrations were available per individual, population pharmacoki-
netic methods were used as previously described  [13] . BMI and 
body surface area (BSA)  [14] were calculated during each visit 
from measured weight and height with the subject wearing a hos-
pital gown and no shoes. Serum creatinine was measured using the 
Roche/Hitachi Creatinine Plus enzymatic assay (Roche Diagnos-
tics, Basel, Switzerland) traceable to an isotope dilution mass spec-
trometry method and serum cystatin C by the immunoturbidimet-
ric method (Roche Cobas 6000, Basel, Switzerland).
 Statistical Methods 
 All linear associations were assessed using Pearson’s correla-
tion coefficient and tested using Fisher’s z transformation. Differ-
ences between pre- and postsurgery measurements were assessed 
using paired t tests, and results are presented as means ± standard 
error. The statistical analyses used SAS, version 9.3 (SAS Institute, 
Cary, N.C., USA) and R, version 2.15 (Free Software Foundation, 
Boston, Mass., USA).
 Metrics for Equation Performance 
 eGFR was calculated using 1 of the following 4 well-validated 
equations: the Modification of Diet in Renal Disease equation us-
ing standardized serum creatinine values  [15] ; the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation using 
serum creatinine only  [5] ; the CKD-EPI equation using serum cys-
tatin C only  [16, 17] , and a recently derived equation that uses both 
serum creatinine and cystatin C (CKD-EPI creat-cystC )  [7] . eGFR 
(milliliters per minute per 1.73 m 2 ) was compared to mGFR (mil-
liliters per minute) after converting them both to milliliters per 
minute or milliliters per minute per 1.73 m 2 . The conversion was 
performed using the following equation: GFR (ml/min) = GFR 
(ml/min/1.73 m 2 ) × BSA/1.73  [18] . Bias was defined as the median 
difference between eGFR and mGFR and expresses the systematic 
deviation from mGFR. We defined precision as the interquartile 
range for the differences since it expresses the variability or disper-
sion around mGFR. Accuracy, which combines bias and preci -
sion, was defined as the root mean square error relative to mGFR 
and the percentage of estimates within 15% and 30% (P 30 ) of the 
mGFR.
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 Results 
 Participant characteristics before and after surgery are 
shown in  table 1 . The 36 study participants were primar-
ily middle-aged, white females who were severely obese 
by BMI criteria. Nearly all participants had baseline se-
rum creatinine and cystatin C levels that were within the 
normal range, and many manifested supranormal (hy-
perfiltering) levels of mGFR before surgery. Participants 
were studied an average of 10 months after bariatric sur-
gery, at which time a mean of 37 kg had been lost (p < 
0.001), with mean mGFR being 17 ± 6 ml/min lower than 
presurgery levels (p = 0.007;  fig. 1 ). mGFR was not sig-
nificantly associated with weight (before: p = 0.12; after: 
p = 0.20) or BSA (before: p = 0.18; after: p = 0.22) before 
or after surgery. Change in mGFR was nonsignificantly 
correlated with change in weight (p = 0.08) but not time 
after surgery (p = 0.49).
Variable
Number of study subjects 36
Age, years 50 ± 11
Female participants, n 28 (78)
Race, n
White
Other
34 (94)
2 (6)
Height, m 1.68 ± 0.11 (1.60, 1.75)
Weight, kg
Before surgery
After surgery
131 ± 33 (108, 140)
94 ± 28 (78, 102)
BMI
Before surgery
After surgery
46 ± 9 (40, 50)
33 ± 8 (28, 36)
BSA, m2
Before surgery
After surgery
2.33 ± 0.32 (2.11, 2.51)
2.02 ± 0.31 (1.83, 2.19)
Time studied after surgery, days 296 ± 103 (221, 369)
Serum creatinine, mg/dl
Before surgery
After surgery
0.81 ± 0.24 (0.64, 0.93)
0.72 ± 0.17 (0.59, 0.83)
Serum cystatin C, mg/l
Before surgery
After surgery
1.12 ± 0.36 (0.91, 1.16)
1.09 ± 0.29 (0.90, 1.23)
mGFR, ml/min
Before surgery
After surgery
117 ± 40 (82, 136)
100 ± 35 (80, 115)
Variable
mGFR, ml/min/1.73 m2
Before surgery
After surgery
87 ± 29 (61, 105)
87 ± 30 (67, 107)
eGFR by MDRD, ml/min/1.73 m2
Before surgery
After surgery
87 ± 20 (73, 104)
98 ± 21 (84, 111)
eGFR by MDRD, ml/min
Before surgery
After surgery
117 ± 29 (93, 141)
114 ± 30 (90, 134)
eGFR by CKD-EPIcreat, ml/min/1.73 m2
Before surgery
After surgery
98 ± 14 (88, 108)
100 ± 17 (92, 110)
eGFR by CKD-EPIcreat, ml/min
Before surgery
After surgery
132 ± 25 (107, 153)
117 ± 26 (100, 136)
eGFR by CKD-EPIcystC, ml/min/1.73 m2
Before surgery
After surgery
67± 22 (57, 78)
68 ± 20 (54, 80
eGFR by CKD-EPIcystC, ml/min
Before surgery
After surgery
89 ± 28 (70, 106)
78 ± 22 (62, 94)
eGFR by CKD-EPIcreat-cystC, ml/min/1.73 m2
Before surgery
Aftersurgery
82 ± 20 (72, 94)
86 ± 19 (74, 101)
eGFR by CKD-EPIcreat-cystC, ml/min
Before surgery
After surgery
109 ± 27 (92, 127)
99 ± 23 (83, 119)
Table 1.  Subject characteristics
 Values represent numbers of patients (percentage) or means ± SD (25th, 75th percentiles), as appropriate. eGFR was converted by 
means of the following equation: eGFR (ml/min) = eGFR (ml/min/1.73 m2) × BSA (m2)/1.73. CKD-EPIcreat = CKD-EPI equation using 
serum creatinine only; CKD-EPIcystC = CKD-EPI equation using serum cystatin C only. CKD-EPIcreat-cystC = CKD-EPI equation using 
serum creatinine and cystatin C.
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 Fig. 1. mGFR before and after surgery. 
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 Serum creatinine dropped significantly after surgery 
(0.1 ± 0.02 mg/dl; p < 0.001), but mean cystatin C did not 
change (0.03 ± 0.03 mg/l; p = 0.20). Weight before and 
after surgery was more closely associated with cystatin C 
(before: r = 0.43, p = 0.009; after: r = 0.49, p = 0.003) than 
serum creatinine (before: r = 0.40, p = 0.02; after: r = 0.41, 
p = 0.01), though change in weight was not correlated 
with either variable. After surgery, mGFR was significant-
ly associated with the inverse of cystatin C (r = 0.38, p = 
0.02). However, this relationship did not reach statistical 
significance in individuals before surgery (r = 0.28, p = 
0.09). The inverse of creatinine was not significantly cor-
related with mGFR either before or after surgery (before: 
r = 0.26, p = 0.13; after: r = 0.11, p = 0.51;  fig. 2 ).
 The overall reliability of GFR-estimating equations is 
shown in  table 2 . After expressing both eGFR and mGFR 
in milliliters per minute, the CKD-EPI creat-cystC was un-
questionably the best overall performing estimating equa-
tion, showing very little bias and P 30 of over 80%. Preci-
sion and accuracy for the CKD-EPI creat-cystC equation fur-
ther improved after surgery, with P 30 increasing to over 
83%. After indexing eGFR and mGFR for BSA (i.e. mak-
ing the units milliliters per minute per 1.73 m 2 ), bias and 
accuracy both improved modestly, while precision after 
surgery fell slightly.
 Discussion 
 Identifying a method that best estimates GFR in bar-
iatric surgery patients before and after weight loss has im-
portant implications for clinical care of obese patients 
and research questions related to the impact of obesity 
and weight reduction on kidney health. In the first study 
of its kind, we evaluated which of the most validated cre-
atinine- and cystatin C-based GFR-estimating equations 
best predicts mGFR in a cohort of bariatric surgery pa-
tients. We found that the CKD-EPI creat-cystC equation per-
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 Fig. 2.  a ,  b mGFR versus inverse creatinine before surgery ( a ; r = 0.26, p = 0.13) and after surgery ( b ; r = 0.11, 
p = 0.51).  c ,  d mGFR versus inverse cystatin C before surgery ( c ; r = 0.28, p = 0.09) and after surgery ( d ; r = 0.38, 
p = 0.02). 
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formed the best before and after surgery, regardless of 
whether or not indexing for BSA was used.
 The influence of severe obesity on the assessment of 
GFR has been insufficiently studied, particularly in light 
of its relatively high prevalence (nearly 16% of the US 
adult population has a BMI  ≥ 35)  [19] and association 
with acute and chronic kidney disease  [20–23] . While 
mGFR is the gold standard for assessing kidney function, 
it involves techniques that are expensive, cumbersome 
and invasive. In addition, mGFR has its limitations, such 
as wide variability within individuals and between meth-
ods and a lack of benefit over eGFR in predicting out-
comes  [24] . eGFR has therefore evolved as the standard 
in the clinical setting. Moreover, even the great majority 
of research studies examining GFR before and after bar-
iatric surgery use creatinine-based GFR-estimating equa-
tions rather than direct measurements  [4, 25, 26] . Never-
theless, the use of eGFR in bariatric surgery patients is 
fraught with potential limitations. Obese persons have 
proportionally greater muscle mass compared to lean in-
dividuals of similar height  [8] . This leads to greater cre-
atinine release into the bloodstream and subsequently 
higher serum creatinine levels when the GFR is constant. 
In addition, obesity is frequently associated with glomer-
ular hyperfiltration  [27] (as noted in our study popula-
tion), which results in lower steady-state serum creati-
Table 2.  Comparison of eGFR and mGFR before and after bariatric surgery
Before surgery  After surgery
mGFR eGFR mGFR eGFR
Bias, median differencea
MDRD 
CKD-EPIcreat
CKD-EPIcystC
CKD-EPIcreat-cystC
–9.0
–18.2
22.6
1.6
–7.0
–13.5
15.6
1.0
–18.5
–20.0
18.2
–4.7
–15.2
–18.7
15.6
–3.9
Precision, IQR of differencea
MDRD 
CKD-EPIcreat
CKD-EPIcystC
CKD-EPIcreat-cystC
41.3
46.9
45.1
35.0
33.8
33.0
36.3
28.4
27.0
33.0
28.4
21.6
30.4
29.6
29.9
23.4
Accuracy, root mean square error 
MDRD 
CKD-EPIcreat
CKD-EPIcystC
CKD-EPIcreat-cystC
0.34
0.37
0.46
0.34
0.26
0.27
0.34
0.26
0.36
0.36
0.35
0.27
0.30
0.30
0.30
0.23
Accuracy, %
P15
MDRD 
CKD-EPIcreat
CKD-EPIcystC
CKD-EPIcreat-cystC
P30
MDRD
CKD-EPIcreat
CKD-EPIcystC
CKD-EPIcreat-cystC
30.6
44.4
30.6
41.7
72.2
58.3
52.8
80.6
30.6
44.4
30.6
41.7
72.2
58.3
52.8
80.6
30.6
30.6
27.8
58.3
55.6
52.8
66.7
83.3
30.6
30.6
27.8
58.3
55.6
52.8
66.7
83.3
 CKD-EPIcreat = CKD-EPI equation using serum creatinine only; CKD-EPIcystC = CKD-EPI equation using 
serum cystatin C only; CKD-EPIcreat-cystC = CKD-EPI equation using both serum creatinine and cystatin C;
IQR = interquartile range; P15 = percentage of estimates that differed from mGFR by more than 15%.
a In milliliters per minute for each left-hand column and milliliters per minute per 1.73 m2 for each right-hand 
column.
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nine levels. The result of these multiple and sometimes 
opposing influences is that the predictive ability of creat-
inine-based GFR-estimating equations, none of which 
were derived or validated in very obese populations  [5, 7, 
15] , is unknown, which is why it is so important to vali-
date eGFR in this particular patient subgroup.
 Cystatin C is an endogenous glomerular filtration 
marker that is being studied as an alternative or comple-
ment to creatinine. There is reason to believe that serum 
cystatin C may correlate more closely with GFR than se-
rum creatinine, particularly in subjects with lower creati-
nine levels  [28, 29] . In addition, it is a better predictor of 
adverse outcomes  [30, 31] . Several studies suggest that 
unlike creatinine, cystatin C is minimally affected by di-
etary meat consumption  [32] or muscle mass  [11, 33] , 
although controversy still exists over the latter issue  [34, 
35] . One particularly compelling report demonstrated 
that cystatin C levels do not drop after traumatic limb 
amputations, further suggesting that, unlike with serum 
creatinine, cystatin C is not influenced by lean mass  [36] . 
The fact that serum cystatin C may be less influenced by 
body composition than creatinine is not only relevant to 
estimating GFR in severely obese individuals (who have 
relatively increased lean mass) but also important to un-
derstanding how best to estimate GFR in very obese per-
sons who undergo intentional weight loss because this 
typically results in loss of both fat and muscle  [37] . In our 
study, serum cystatin C was observed to have a stronger 
correlation with mGFR than did serum creatinine. In ad-
dition, cystatin C also had a statistically significant asso-
ciation with body weight (though weight did not have a 
similar association with mGFR). These findings suggest 
that while cystatin C appears to be more closely linked to 
mGFR and is itself a superior marker of GFR in this pop-
ulation, it is also likely to be influenced by additional fac-
tors. Perhaps adipose mass or its secreted inflammatory 
products account for the observed relationship between 
weight and cystatin C  [38, 39] .
 An additional issue pertinent to estimating GFR in 
bariatric surgery patients is the standard of indexing of 
GFR for BSA in GFR-estimating equations. Adjusting for 
BSA allows for comparison of GFR between individuals 
of differing body size, with the underlying assumption 
being that physiological parameters like GFR are propor-
tional to body size. This is supported by allometric scaling 
principles in which larger-sized organisms produce a 
greater metabolic load that leads to a greater filtration ca-
pacity  [40] . However, as we and others have pointed out 
 [41, 42] , applying these concepts to the obese individual 
is misleading. Obese persons are different than lean sub-
jects in that increases in weight are mostly due to excess 
adiposity, not lean mass. This difference is important be-
cause adipose mass does not significantly contribute to 
metabolic load  [43] . Therefore, adjusting for BSA in obese 
individuals underestimates the true GFR. Consistent with 
our concern is the fact that we observed no significant re-
lationship between mGFR and parameters like weight or 
BSA in this severely obese population. Furthermore, if 
one is interested specifically in determining the change in 
GFR after weight reduction  within a particular individual, 
then adjusting for BSA is unnecessary because the num-
ber of nephrons does not change as the individual loses 
weight. While the CKD-EPI creat-cystC equation performed 
similarly with and without indexing for BSA, we believe 
that indexing should preferably be avoided when study-
ing changes within an individual bariatric surgery pa-
tient.
 Several prominent, well-validated GFR-estimating 
equations were evaluated in our study population. Though 
the CKD-EPI creat-cystC equation was less precise than pre-
viously reported in leaner populations  [5, 7] , its bias and 
accuracy were similar to those of equations used in stan-
dard clinical practice (e.g. Modification of Diet in Renal 
Disease equation, CKD-EPI equation using serum creati-
nine only)  [5] . Interestingly, the combination of serum 
cystatin C and creatinine greatly improved the predictive 
value of eGFR over individual creatinine- or cystatin C-
based equations. This is surprising, as we expected the 
cystatin C-based equation to perform better than creati-
nine-based equations, which it did not. We hypothesize 
that various influences on creatinine and cystatin C that 
are unrelated to GFR balanced each other and resulted in 
improved overall performance.
 Our study has several strengths. It is the first study to 
assess the predictive value of estimating equations before 
and after bariatric surgery-induced weight loss using a 
cohort of bariatric surgery patients in whom GFR was di-
rectly measured. It therefore provides novel and impor-
tant information that can be applied to clinical practice 
and the research setting. It also has some limitations. Our 
study is of a relatively modest size (though we are un-
aware of larger studies directly measuring GFR in bariat-
ric surgery patients). The study was performed in patients 
with normal baseline serum creatinine levels, so caution 
should be used when applying the findings to patients 
with existing kidney disease. Body composition measure-
ments were not available for the cohort, which could have 
helped further define the influence of lean versus fat mass 
on mGFR. We did not specifically exclude patients who 
may have had diseases (hypothyroidism) or taken medi-
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cations (glucocorticoids) that could influence cystatin C 
levels. However, such issues were unlikely to affect our 
findings in light of the relatively healthy nature of our 
study population. We also did not measure dietary pro-
tein consumption, which could influence serum creati-
nine levels though is unlikely to influence mGFR  [44] .
 In conclusion, cystatin C is more strongly associated 
with mGFR than is serum creatinine in bariatric surgery 
patients, while the CKD-EPI creat-cystC equation best pre-
dicted mGFR both before and after surgery.
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